Uli Brödl, MD, assumed the role of Head of Research & Development, Chief Scientific Officer and Member of the Corporate Executive Board in February 2025. He has more than 15 years of industry experience and joined Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim’s Venture Fund Investment Committee.

In his most recent roles, Uli oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli led Boehringer Ingelheim’s Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Canada Incubator, an innovation lab to develop innovative healthcare solutions.